Rechallenge therapy versus tyrosine kinase inhibitor (TKI . . . Abstract Currently, the standard third-line treatment options for advanced metastatic colorectal cancer (mCRC) include regorafenib, fruquintinib, and trifluridine tipiracil (TAS-102), but these drugs have limited clinical efficacy This study aims to evaluate the efficacy and survival outcomes of tyrosine kinase inhibitor (TKI) versus chemotherapy rechallenge in third-line treatment for
Lost in translation: Revisiting the use of tyrosine kinase . . . Patients with advanced or metastatic colorectal cancer ( (m)CRC) have limited effective treatment options resulting in high mortality rates A better understanding of the molecular basis of this disease has led to growing interest in small molecule tyrosine kinase inhibitors (TKIs) for its treatment
Multi-omics characterization of response to tyrosine kinase . . . Multi-omics characterization of response to tyrosine kinase inhibitor plus immunotherapy in MSS pMMR metastatic colorectal cancer: A multicenter biomarker study If you have the appropriate software installed, you can download article citation data to the citation manager of your choice
Abstract 6002: Tyrosine kinase inhibitor (TKI) plus PD-1 . . . Tyrosine kinase inhibitor (TKI) plus PD-1 blockade in TKI-responsive MSS pMMR metastatic colorectal adenocarcinoma (mCRC): Results of a multicenter, phase II trial (TRAP) [abstract] In: Proceedings of the American Association for Cancer Research Annual Meeting 2025; Part 1 (Regular Abstracts); 2025 Apr 25-30; Chicago, IL
Anlotinib Combined With Sintilimab as First-line Treatment . . . Diagnosis of any malignancy other than advanced colorectal cancer within the 5 years preceding the start of study treatment, except for carcinoma in situ of the cervix, cured basal cell carcinoma, or bladder epithelial tumors